Plasma receptor for advanced glycation end products and clinical outcomes in acute lung injury

C S Calfee,1,2 L B Ware,3 M D Eisner,1,4 P E Parsons,5 B T Thompson,6,7 N Wickersham,3 M A Matthy,1,2,4 the NHLBI ARDS Network

ABSTRACT

Objectives: To determine whether baseline plasma levels of the receptor for advanced glycation end products (RAGE), a novel marker of alveolar type I cell injury, are associated with the severity and outcomes of acute lung injury, and whether plasma RAGE levels are affected by lower tidal volume ventilation.

Design, setting and participants: Measurement of plasma RAGE levels from 676 subjects enrolled in a large randomised controlled trial of lower tidal volume ventilation in acute lung injury.

Measurements and main results: Higher baseline plasma RAGE was associated with increased severity of lung injury. In addition, higher baseline RAGE was associated with increased mortality (OR for death 1.38 (95% CI 1.13 to 1.68) per 1 log increment in RAGE; p = 0.002) and fewer ventilator free and organ failure free days in patients randomised to higher tidal volumes. These associations persisted in multivariable models that adjusted for age, gender, severity of illness and the presence of sepsis or trauma. Plasma RAGE was not associated with outcomes in the lower tidal volume group (p = 0.09 for interaction in unadjusted analysis). In both tidal volume groups, plasma RAGE levels declined over the first 3 days; however, the decline was 15% greater in the lower tidal volume group (p = 0.02; 95% CI 2.4% to 25.0%).

Conclusions: Baseline plasma RAGE levels are strongly associated with clinical outcomes in patients with acute lung injury ventilated with higher tidal volumes. Lower tidal volume ventilation may be beneficial in part by decreasing injury to the alveolar epithelium.

Acute lung injury (ALI) and its more severe form, the acute respiratory distress syndrome (ARDS), remain a major cause of acute respiratory failure and death in critically ill patients. Despite therapeutic advances in ventilation strategy and fluid management, mortality and morbidity remain high, and no effective pharmacological therapies for the syndrome have yet been identified. Increased understanding of the pathophysiology and pathogenesis of this syndrome, identification of predictors of poor outcomes and insight into the mechanisms of benefit of effective therapies such as low tidal volume ventilation may lead to further therapeutic advances.

The integrity of the alveolar–capillary barrier is critical to normal pulmonary function. Furthermore, impaired alveolar fluid clearance is known to be a central feature of the pathogenesis of ALI/ARDS. Type I epithelial cells cover 95% of the surface area of the alveoli and play a key role in epithelial integrity and alveolar fluid clearance. Given these important functions, the magnitude of damage to the alveolar type I cell could be a major determinant of the severity of ALI/ARDS and of its clinical outcomes. However, the search for a reliable, easily measured marker of alveolar type I cell injury in humans has proved difficult, and thus the importance of alveolar type I cell damage in humans with ALI remains unclear.

The receptor for advanced glycation end products (RAGE) was recently identified as a promising new marker of alveolar type I cell injury. RAGE is a member of the immunoglobulin superfamily that acts as a multi-ligand receptor and is involved in propagating inflammatory responses. Immuno-electron microscopy has demonstrated that RAGE expression in the lung is primarily located on the basal surface of alveolar type I cells. Although RAGE is produced by other cell types in other organs, such as vascular endothelium and nervous tissues, and is therefore not specific for alveolar type I cell injury, it is most abundant in the lung. In a murine model of ALI, elevated RAGE levels in bronchoalveolar lavage fluid and serum were directly related to the severity of experimentally induced lung injury. Similarly, in human subjects, plasma RAGE levels were significantly higher in patients with ALI than in patients with hydrostatic pulmonary oedema or normal controls. Elevated plasma RAGE levels have also been associated with an increased duration of mechanical ventilation and ICU length of stay in patients following lung transplantation. However, the potential pathogenic and prognostic value of RAGE has not been studied in patients with ALI.

The objective of this study was to determine whether plasma levels of RAGE are associated with the severity and clinical outcomes of ALI/ARDS in subjects enrolled in the ARDS Network’s trial of a lower tidal volume, plateau pressure limited ventilation strategy. We hypothesised that increased baseline levels of RAGE would be associated with increased severity of ALI/ARDS and with poor clinical outcomes, including increased mortality and fewer ventilator free and organ failure free days. Furthermore, from a mechanistic perspective, we hypothesised that plasma RAGE levels measured at 3 days after enrolment would be preferentially decreased by a low tidal volume ventilation strategy.

METHODS

Clinical data and biological samples for this study were obtained from patients enrolled in a randomised controlled trial of lower tidal volume, plateau pressure limited ventilation conducted by
Acute lung injury

the National Heart, Lung and Blood Institute’s ARDS Network.2 This trial enrolled 861 patients to test the hypothesis that ventilation with a lower tidal volume, plateau pressure limited strategy would reduce mortality in patients with ALI.2 The details and results of the clinical trial have been previously published in full.2 Briefly, patients were randomised to ventilation with a tidal volume of either 6 or 12 ml/kg predicted body weight; once the benefit of the lower tidal volume strategy had been demonstrated, an additional 41 patients were assigned to the lower tidal volume to complete a factorised trial of lisofylline versus placebo,17 and these patients are also included in this analysis. All patients were followed until death, 180 days or until discharge home with unassisted breathing. The trial demonstrated a significant reduction in 180 day mortality in the lower tidal volume treatment group (31% vs 40%, p = 0.007). In a factorial design, ketoconazole18 and lisofylline17 were also administered to subsets of patients as investigational therapies for ALI, neither of which affected mortality. Inclusion and exclusion criteria are described in the original publication.2 The institutional review boards of all involved hospitals approved the trial.2

Assay procedures

We measured baseline (day 0, pre-randomisation) and day 3 plasma levels of RAGE using a commercially available enzyme linked immunoassay (Human RAGE Quantikine ELISA; R&D Systems, Minneapolis, Minnesota, USA) in 676 patients from the original clinical trial. RAGE levels were not measured in all 902 patients because of limited plasma availability.

Statistical methods

Statistical analysis was performed with STATA/SE 9.2 (College Station, Texas, USA). To compare baseline levels of RAGE in two group comparisons, we used Mann–Whitney rank sum tests; for multiple group comparisons, we used the Kruskal–Wallis test. Because RAGE levels were not normally distributed, we applied natural log transformation to the plasma RAGE levels in order to apply linear models. We first tested the impact of RAGE on mortality in an unadjusted logistic regression and then created a multivariable logistic model to control for baseline clinical features that may have affected outcomes, including age, gender, sepsis or trauma as aetiologies of lung injury, and severity of illness, as reflected by Acute Physiology and Chronic Health Evaluation (APACHE) III score.19 These covariates were selected on the basis of the bivariate analysis results (all were associated with mortality, with p<0.05, with the exception of gender, which was associated with baseline RAGE) and prior clinical research about predictors of mortality in ALI.20 We performed similar analyses using linear regression models for the outcomes of ventilator free days and organ failure free days. In addition, in a pre-specified analysis, plasma RAGE levels were divided into quartiles to test for a non-linear relationship with outcomes in similar regressions. All analyses were stratified by ventilation strategy because of an observed interaction between baseline plasma RAGE level and ventilation strategy; this interaction was the only interaction tested and was initially sought after a difference in the odds ratios for death stratified by ventilation strategy was observed. Unstratified analyses are presented in the online supplement. A p value of <0.20 was considered potentially important for interactions21; for all other analyses, a p value of <0.05 was considered significant. Logistic models were checked using the Hosmer–Lemeshow test and the link test22; linear models were evaluated using residual based diagnostics. Analysis of covariance was used to test the impact of lower tidal volume ventilation on the change in RAGE levels from day 0 to day 3.

RESULTS

Baseline clinical characteristics of subjects

Baseline plasma samples were available for RAGE measurements in 676 of the 902 original study subjects. The clinical characteristics of subjects who had plasma samples available were similar to those who did not have plasma samples available (table 1), with the exception of a lower incidence of trauma as the aetiology of ALI and a slightly lower mean APACHE III score. Baseline plasma RAGE levels did not differ by clinical risk factor for ALI (p = 0.54) or by race/ethnicity but did differ by gender (median in men 5536 pg/ml vs 3360 pg/ml in women; p<0.0001). Plasma RAGE levels did not differ based on the presence of end stage renal disease, diabetes, cirrhosis of the liver, a history of malignancy or immunosuppression, or a history of the acquired immunodeficiency syndrome.

Severity of ALI/ARDS

Higher baseline levels of plasma RAGE were significantly associated with more severe ALI/ARDS, as reflected by measures of pulmonary physiology, including lower fractional inspired oxygen/arterial oxygen tension (PaO2/FiO2) ratio, lower compliance, and higher clinical and radiographic lung injury scores (figs 1 and 2).23 Similarly, higher baseline plasma RAGE levels were associated with higher pre-randomisation tidal volume (r = 0.12; p = 0.002) and plateau pressure (r = 0.22; p<0.0001). Higher baseline levels of plasma RAGE were also associated with higher APACHE scores (r = 0.17; p<0.0001).

Clinical outcomes

In unadjusted analyses, baseline plasma RAGE was strongly associated with poor clinical outcomes. Baseline RAGE was significantly higher in subjects who died compared with those...
who survived (median (IQR) in non-survivors 5327 (2250 to 10112) pg/ml vs in survivors 3618 (1916 to 7402) pg/ml; p = 0.001). However, on further analysis of the association between baseline plasma RAGE and death, an interaction between baseline plasma RAGE and ventilation strategy was detected (p = 0.09). When the analysis was stratified by ventilation strategy, baseline RAGE was predictive of death only in the group randomised to the 12 ml/kg strategy (fig 3, table 2) (odds ratio (OR) per 1 log increment in RAGE 1.38; 95% confidence interval (CI) 1.13 to 1.68; p = 0.002). Baseline RAGE was not predictive of death in the lower tidal volume group (OR 1.07; 95% CI 0.86 to 1.32; p = 0.53).

Baseline plasma RAGE was also strongly associated with increased morbidity from ALI in the 12 ml/kg ventilation group (table 3). Specifically, for every 1 log increase in plasma RAGE, ventilator free days decreased by 1.57 (95% CI −2.57 to −0.56 days; p = 0.002) and organ failure free days decreased by 2.44 (95% CI −3.44 to −1.44 days, p<0.001). Baseline plasma RAGE was not associated with increased morbidity in the 6 ml/kg group (table 3).

Multivariable models

The strong association between baseline plasma RAGE and poor clinical outcomes in the 12 ml/kg group persisted in multivariable models. After adjusting for age, gender, APACHE III score and the presence of sepsis or trauma as a risk factor for ALI, higher baseline plasma RAGE remained strongly associated with an increased odds of death at 180 days in the 12 ml/kg group (table 2). Additional adjustments for pre-existing diabetes and end stage renal disease had no appreciable impact on the results of these regressions; similarly, including all precipitating risk factors for ALI in the model had no appreciable impact on the results. As with the mortality analyses, higher baseline plasma RAGE remained associated with a lower number of ventilator free and organ failure free days in multivariable linear models in the 12 ml/kg group, adjusting for the same clinical covariates (table 3). Multivariable models revealed no association between baseline RAGE and clinical outcomes in the 6 ml/kg group (table 3).

To further study the relationship of baseline plasma RAGE to clinical outcomes, the multivariable analyses were repeated using quartiles of RAGE, again controlling for the same clinical covariates (age, gender, APACHE III score, sepsis and trauma) and stratifying by ventilation strategy. In the 12 ml/kg group, this analysis demonstrated an increased risk of death for the highest quartile of RAGE compared with the lowest quartile (OR 2.73, 95% CI 1.31 to 5.68; overall p = 0.003) (table 4). In the 6 ml/kg group, RAGE by quartile was not significantly associated with mortality (data not shown). Linear regression

Figure 1  Higher baseline plasma receptor for advanced glycation end products (RAGE) was associated with more severe disturbances in pulmonary physiology (n = 676 for fractional inspired oxygen/arterial oxygen tension (PaO₂/FiO₂); n = 522 for compliance). Median and interquartile range are shown. *p = 0.008; †p = 0.01

Figure 2  Increasing clinical and radiographic lung injury scores (LIS), reflecting increasing severity of lung injury, were associated with increasing baseline plasma receptor for advanced glycation end products (RAGE) (n = 669). Median and interquartile range are shown. For clinical LIS: Kruskal–Wallis p = 0.0008; test for trend p<0.001. For radiographic LIS: Kruskal–Wallis p = 0.001; test for trend p<0.001.

Figure 3  Baseline plasma receptor for advanced glycation end products (RAGE) by survival status, stratified by ventilation strategy (n = 676). Baseline plasma RAGE was associated with death at 180 days only in the 12 ml/kg group. Median (interquartile range) plasma RAGE in each group is shown. Comparisons were made using the Mann–Whitney (Wilcoxon) rank sum test.
models for ventilator free days and organ failure free days using quartiles of RAGE revealed similar findings (table 4).

Impact of lower tidal volume strategy
The impact of the lower tidal volume ventilation strategy on the change in RAGE levels over the first 3 days of the study was measured using analysis of covariance. There were 599 patients with paired day 0 and day 3 samples available for analysis. In both the 6 ml/kg and 12 ml/kg groups, plasma RAGE levels declined over the first 3 days; however, there was a 15% greater decline in the 6 ml/kg group compared with the 12 ml/kg group (p = 0.02; 95% CI 2.4% to 25.0%) (fig 4).

Given the observed interaction between baseline plasma RAGE and ventilator strategy, we compared the effect of low tidal volume ventilation on mortality in the highest compared with the lowest quartile of baseline RAGE. In the highest quartile of baseline RAGE, the OR for death in subjects treated with lower tidal volume ventilation was 0.36 compared with those treated with higher tidal volumes (95% CI 0.19 to 0.67; p = 0.001). In comparison, in the lowest quartile of baseline RAGE, the OR for death in subjects treated with lower tidal volumes was 0.52 (95% CI 0.26 to 1.00; p = 0.05).

DISCUSSION
In a large, multicentre, randomised, controlled trial of ventilation strategy in ALI, higher baseline plasma RAGE levels were associated with worse clinical outcomes in patients randomised to higher tidal volumes, including increased mortality and fewer ventilator free and organ failure free days. These associations persisted even after adjusting for other important determinants of outcome, including age, aetiology of ALI and severity of illness. In patients randomised to lower tidal volumes, plasma RAGE was not predictive of outcomes. Plasma RAGE was associated with measures of severity of lung injury, including PaO\textsubscript{2}/FiO\textsubscript{2}, quasi-static compliance and lung injury score. Furthermore, lower tidal volume ventilation amplified the decline in RAGE levels over the first 3 days of the study, suggesting that ventilation with a 6 ml/kg strategy may cause less injury to alveolar type I cells than ventilation with higher tidal volumes.

Although RAGE is not specific for alveolar epithelial injury, several findings in this study and in prior work provide supportive evidence that the primary source of plasma RAGE in our patients is the alveolar type I cell. In our previous work on RAGE in animal models of ALI, both acid aspiration and lipopolysaccharide induced lung injury resulted in RAGE release into the bronchoalveolar lavage fluid at much higher levels than in plasma, suggesting a pulmonary source for plasma RAGE in the setting of ALI.\textsuperscript{13} A similar pattern was found in human oedema fluid and plasma samples from subjects with ALI.\textsuperscript{13} Likewise, in a recently published isolated perfused human lung preparation in which the lung is the only possible source of RAGE, perfusate levels of RAGE were significantly and inversely associated with alveolar fluid clearance, suggesting that RAGE

Table 2  Baseline plasma RAGE and death at 180 days among patients with ALI/ARDS, stratified by ventilator strategy

<table>
<thead>
<tr>
<th>Model</th>
<th>Tidal volume group (ml/kg)</th>
<th>OR for death at 180 days (95% CI)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline plasma RAGE (1 log increment), unadjusted</td>
<td>12</td>
<td>1.38 (1.13 to 1.68)</td>
<td>0.002</td>
</tr>
<tr>
<td>Baseline plasma RAGE (1 log increment), multivariable*</td>
<td>12</td>
<td>1.41 (1.12 to 1.78)</td>
<td>0.004</td>
</tr>
<tr>
<td>Baseline plasma RAGE (1 log increment), unadjusted</td>
<td>6</td>
<td>1.07 (0.86 to 1.32)</td>
<td>0.53</td>
</tr>
<tr>
<td>Baseline plasma RAGE (1 log increment), multivariable*</td>
<td>6</td>
<td>1.03 (0.81 to 1.31)</td>
<td>0.80</td>
</tr>
</tbody>
</table>

*Multivariable model adjusts for age, gender, APACHE III score, and presence of sepsis or trauma as ALI risk factors. Model checking performed using residual based diagnostics. All transformations use natural logarithms.

<table>
<thead>
<tr>
<th>Ventilator group</th>
<th>Model</th>
<th>Mean difference in ventilator free days* (95% CI)</th>
<th>p Value</th>
<th>Mean difference in organ failure free days (95% CI)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>12 ml/kg</td>
<td>Baseline plasma RAGE (1 log increment), unadjusted</td>
<td>−1.57 (−2.57 to −0.56)</td>
<td>0.002</td>
<td>−2.44 (−3.44 to −1.44)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>Baseline plasma RAGE (1 log increment), multivariable*</td>
<td>−1.15 (−2.10 to −0.20)</td>
<td>0.02</td>
<td>−1.98 (−2.94 to −1.03)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>6 ml/kg</td>
<td>Baseline plasma RAGE (1 log increment), unadjusted</td>
<td>−0.57 (−1.59 to 0.45)</td>
<td>0.27</td>
<td>−1.01 (−2.06 to 0.03)</td>
<td>0.06</td>
</tr>
<tr>
<td></td>
<td>Baseline plasma RAGE (1 log increment), multivariable*</td>
<td>−0.24 (−1.29 to 0.80)</td>
<td>0.65</td>
<td>−0.72 (−1.73 to 0.30)</td>
<td>0.17</td>
</tr>
</tbody>
</table>

*Multivariable model adjusts for age, gender, APACHE III score, and presence of sepsis or trauma as ALI risk factors. Model checking performed using residual based diagnostics. All transformations use natural logarithms.
Acute lung injury

Table 4  Quartiles of RAGE and clinical outcomes in the 12 ml/kg group

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Predictor</th>
<th>Mean effect, compared with first quartile (95% CI)</th>
<th>p Value for predictor</th>
<th>p Value for trend</th>
</tr>
</thead>
<tbody>
<tr>
<td>Odds ratio for death at 180 days</td>
<td>Second quartile RAGE</td>
<td>0.77 (0.37 to 1.57)</td>
<td>0.003</td>
<td>0.008</td>
</tr>
<tr>
<td></td>
<td>Third quartile RAGE</td>
<td>0.86 (0.41 to 1.80)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fourth quartile RAGE</td>
<td>2.73 (1.31 to 5.68)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ventilator free days</td>
<td>Second quartile RAGE</td>
<td>0.1 (−3.0 to 3.1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Third quartile RAGE</td>
<td>0.1 (−3.0 to 3.4)</td>
<td>0.01</td>
<td>0.01</td>
</tr>
<tr>
<td></td>
<td>Fourth quartile RAGE</td>
<td>−4.2 (−7.3 to −1.1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organ failure free days</td>
<td>Second quartile RAGE</td>
<td>−2.4 (−5.5 to 0.8)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Third quartile RAGE</td>
<td>−2.3 (−5.6 to 1.0)</td>
<td>0.001</td>
<td>0.0003</td>
</tr>
<tr>
<td></td>
<td>Fourth quartile RAGE</td>
<td>−6.4 (−9.5 to −3.2)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

All analyses adjusted for age, gender, APACHE III, sepsis and trauma.

APACHE, Acute Physiology and Chronic Health Evaluation; RAGE, receptor for advanced glycation end products.

quantitatively reflects alveolar epithelial damage. In the current study, the finding that plasma RAGE levels were associated with the severity of pulmonary physiological disturbances (PaO2/FiO2 ratio, compliance and plateau pressure) also supports an alveolar epithelial source of RAGE.

Despite this evidence, it is important to emphasise that non-pulmonary sources of RAGE may contribute to plasma levels in the setting of ALI, including release from non-pulmonary large vessel endothelial surfaces and systemic inflammation. Moreover, plasma RAGE levels may have been affected by the permeability of the alveolar–capillary interface, although this phenomenon would if anything strengthen its utility as a marker of lung injury. While the precise function of RAGE remains unclear, evidence is mounting that RAGE plays an important role in regulating inflammation. The primary ligands for RAGE are advanced glycation end products (AGE), non-enzymatically glycated adducts of endogenous proteins, lipids and nucleic acids whose formation is increased in the presence of hyperglycaemia or oxidant stress. In addition to AGE, RAGE has several alternative ligands, including proinflammatory molecules such as S100 and high mobility group box 1. RAGE–ligand interaction mediates nuclear factor κB activation and seems thereby to play a role in propagating and sustaining systemic inflammatory responses. Thus although we set out to study RAGE as a marker of alveolar epithelial injury, it is possible that the association between plasma RAGE and clinical outcomes of ALI observed in our study derives in part from the role of RAGE in an inflammatory cascade rather than purely from its release from alveolar type I cells. If plasma RAGE levels measured in our study primarily reflect the role of RAGE in inflammation, then the interaction between RAGE and ventilator strategy lends further credence to the hypothesis that low tidal volume ventilation decreases systemic inflammation.

The finding of effect modification in this study—that is, that the predictive value of RAGE differed by tidal volume strategy—was particularly informative. If plasma RAGE primarily reflects alveolar epithelial injury, this interaction implies that patients with more severe alveolar epithelial injury are most susceptible to the additional ventilator induced lung injury that may be generated by higher tidal volumes. This interpretation is reinforced by the finding that lower tidal volume ventilation preferentially amplified the decline in RAGE levels over the first 5 days of the study. Lower tidal volume ventilation preferentially affects the plasma levels of several biomarkers that have prognostic value in ALI/ARDS, including markers of inflammation (interleukins 6 and 8), alveolar type II cell injury (surfactant protein D) and soluble tumour necrosis factor receptor 1, which may reflect neutrophil–endothelial interaction and/or epithelial injury. When taken in concert with the finding of effect modification by lower tidal volume ventilation, the amplified decline in RAGE levels over time in patients in the 6 ml/kg group provides important evidence that a lung protective ventilation strategy is effective at least in part by decreasing injury to the alveolar epithelium.

The results of this study also suggest that the degree of injury to the alveolar type I cell is an important determinant of outcomes in human ALI. Type I cells cover the vast majority of the alveolar surface and form a key component of the alveolar capillary barrier. In addition to this role, type I cells have been traditionally thought to be primarily responsible for gas exchange and osmotically driven water transport whereas type II cells have been thought to be primarily responsible for surfactant production, ion transport and alveolar fluid clearance. Recent research has suggested, however, that type I cells play a key role in ion and vectorial fluid transport as well, making their function all the more critically relevant to the pathogenesis and resolution of lung injury, since impaired alveolar fluid clearance is clearly linked to poor clinical outcomes in ALI. The specific association between alveolar type I cell damage and the severity of lung injury has been

Figure 4  Plasma levels of receptor for advanced glycation end products (RAGE) declined in both the 6 ml/kg and 12 ml/kg groups over the first 3 days of the study (n = 599); however, the decline was 14.6% greater in the lower tidal volume group (p = 0.02; 95% CI 2.4% to 25.0%). Note the y axis scale differs between the two sides of the figure.

demonstrated in rat models of ALI, but the lack of a human marker of type I cell injury has precluded quantitative testing of this relationship (and the relationship of type I cell injury to clinical outcomes) in human studies until now.

The finding that plasma RAGE levels differed at baseline by gender was surprising and has not to our knowledge been reported in other clinical settings. Men on average have larger lungs than women, and thus by definition should have more alveolar epithelial cells; however, the magnitude of difference detected in this sample seems unlikely to be due to differences in lung mass. Although gender has not been associated with outcomes in most studies of ALI, we included gender as a covariate in all of our multivariable models to account for any confounding that might have occurred because of this difference in baseline plasma RAGE levels.

This study has some limitations. Firstly, plasma RAGE was not measured in all participants in the original trial, but only in subjects for whom plasma samples were still available. Although our analyses revealed few differences between subjects who had plasma available and those who did not, it remains possible that systematic factors contributed in some way to plasma availability. Secondly, the selection of potential confounders for the multivariable models was limited to clinical data collected by the original ARDS Network studies. Several chronic diseases that may affect clinical outcomes may also impact on RAGE levels; for instance, subjects with diabetes mellitus and end stage renal disease have been shown to have elevated levels of plasma RAGE, whereas subjects with coronary artery disease, rheumatoid arthritis, Alzheimer’s disease and essential hypertension have been shown to have decreased levels of plasma RAGE. Although we were able to control for diabetes mellitus and pre-existing dialysis dependent renal failure in sensitivity analyses (and demonstrate that they had no impact on our results), coronary artery disease, rheumatoid arthritis, Alzheimer’s disease and hypertension were not recorded in the original dataset. Thus it is possible that chronic diseases present in some study subjects are unmeasured confounders in our analyses. Thirdly, the finding of an interaction between baseline RAGE and ventilation strategy should, like all subgroup analyses, be interpreted with caution, particularly as the criteria used to determine the potential importance of the interaction were less stringent than for other analyses. The use of a less stringent p value for interaction analyses is common in the epidemiological literature although the optimum cut-off remains controversial. Moreover, when the data are analysed without stratification to account for the interaction, baseline RAGE is significantly predictive of death and the other key clinical outcomes in the cohort as a whole in both unadjusted and multivariable models (data available in online supplement). Finally, plasma samples used in this study had been stored for several years at −70°C; whether this extended storage has any effects on plasma biomarker levels remains unknown.

In conclusion, in this analysis of data from a large randomised controlled trial, baseline levels of plasma RAGE were independently associated with clinical outcomes in ALL ARDS in patients randomised to traditional higher tidal volumes. In this group, higher baseline plasma RAGE levels were associated with increased mortality and fewer ventilator free and organ failure free days. In addition, lower tidal volume ventilation amplified the decline in RAGE levels over time. These findings provide new evidence that lower tidal volume ventilation may be beneficial at least in part by decreasing injury to the alveolar epithelium.

Acknowledgements: Details of acknowledgements are in the supplementary material online.

Funding: This work was supported by contracts (N01-HR-46054, 46055, 46056, 46057, 46058, 46059, 46060, 46061, 46062, 46063, and 46064) from the National Heart, Lung, and Blood Institute (NHLBI). IAM was supported by NHLBI Grant HL 51896. CSC was supported by K23RR024130 from the National Center for Research Resources, a component of NIH, and by the Flight Attendant Medical Research Institute. LBW was supported by NHLBI Grant HL081332.

Competing interests: None.

Ethics approval: Ethics approval was obtained.

REFERENCES
Six minute walk distance is a useful predictor of survival in lung transplant recipients

Six minute walk distance (6MWD) is routinely used as part of the assessment process for lung transplant recipients. However, there is a paucity of data supporting the impact of baseline 6MWD on transplant outcomes in advanced lung diseases.

In this study, clinical information was prospectively collected over a 28-month period from 376 patients with diverse lung diseases awaiting lung transplantation at two centres. Investigators compared data before transplantation, after transplantation and during the overall study period, with death as the primary end point.

In each analysis every 500 foot increase in the baseline 6MWD was found to be a significant predictor of survival. No other variables such as age, body mass index, forced expiratory volume in 1 s, waiting list times and native lung disease were significantly associated with survival. There was no significant interaction between the effects of 6MWD and the underlying lung disease.

The authors conclude that 6MWD is an important tool for assessing survival in lung transplant recipients for all native lung diseases. However, the study was underpowered to assess mortality in the individual lung diseases and is not generalisable to all patient populations with end stage disease. Furthermore, they do not report on any co-morbidities or physical disability which could affect 6MWD. More research is required in assessing 6MWD to determine if a single baseline measurement or subsequent measurements over time offer a better prognostic tool in lung transplant candidates. The authors also suggest that rehabilitative measures that improve 6MWD may, in turn, affect survival following lung transplantation. This requires further study.


V Ganagaram

Correspondence to: Dr V Ganagaram, Department of Respiratory Medicine, Papworth Hospital, Cambridgeshire, UK; venkatgangaram@doctors.net.uk
Plasma receptor for advanced glycation end products and clinical outcomes in acute lung injury

C S Calfee, L B Ware, M D Eisner, P E Parsons, B T Thompson, N Wickersham, M A Matthay and the NHLBI ARDS Network

Thorax 2008 63: 1083-1089 originally published online June 19, 2008
doi: 10.1136/thx.2008.095588

Updated information and services can be found at:
http://thorax.bmj.com/content/63/12/1083

These include:

Supplementary Material
Supplementary material can be found at:
http://thorax.bmj.com/content/suppl/2008/11/10/63.12.1083.DC1

References
This article cites 38 articles, 8 of which you can access for free at:
http://thorax.bmj.com/content/63/12/1083#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Adult respiratory distress syndrome (111)
- Clinical trials (epidemiology) (557)
- Epidemiologic studies (1829)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/